tirzepatide mayo clinic Weight-loss drug may lower heart failure deaths Mayo Clinic retrospective data suggests

Scientists from the WHO recently wrote: "The approval of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of obesity creates potential for a transformation of the whole health system that could halt and reverse the global obesity pandemic through prevention and effective integrated management." Growing crisis South Africa is grappling with dual diabetes and obesity epidemics, on top of the HIV and TB epidemics, but is not responding effectively, resulting in high obesity and diabetes-related deaths

This dual GIP/GLP-1 receptor agonist slows gastric emptying to control blood sugar and promote satiety, which can trigger nausea, vomiting, and gastrointestinal discomfort

Great service

As the #1 AI Doctor, we offer free AI doctor visits that provide you with fast, personalized, and evidence-based medical advice

Cost and access considerations represent practical limitations for many patients

SGLT2 inhibitors are associated with an increased risk of genital mycotic infections due to their mechanism of action, which increases glucose excretion in the urine